BMS signs $674m GenAI drug discovery deal with VantAI

The partnership will focus on designing molecular glues for unspecified therapeutic targets.

Feb 14, 2024 - 18:00

BMS signs $674m GenAI drug discovery deal with VantAI

The partnership will focus on designing molecular glues for unspecified therapeutic targets.

Read the original article

Tags:

Previous Article

FDA cracks down on online retailers selling unapproved GLP-1 agonists

Grifols gears up for FDA approval of fibrinogen replacement therapy

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Latest data shows millions of eligible Americans have been disenrolled from Medicaid

Latest data shows millions of eligible Americans have b...

Nov 3, 2023

Singapore accepts Everest’s NDA for IgA nephropathy treatment

Singapore accepts Everest’s NDA for IgA nephropathy tre...

Apr 6, 2023

STAT+: 3 issues to watch in pharma in 2024

STAT+: 3 issues to watch in pharma in 2024

Dec 27, 2023